DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20163102

A cross-sectional study to assess the adverse effect profile of second generation antipsychotics: risperidone, olanzapine and quetiapine

Scandashree K., Praveenkumar B., Padmaja Udaykumar

Abstract


Background: Pharmacovigilance is the scientific approach to a drug related problem.  Psychotropic drugs are known to cause several adverse drug reactions (ADRs).  This study aimed to assess the adverse effect profile of 3 second generation antipsychotics-risperidone, olanzapine and quetiapine in patients on monotherapy of any of these second generation antipsychotics.

Methods: This was a hospital based cross-sectional study conducted in psychiatric outpatient department of Psychiatry in Father Muller Mental Health Centre, Mangalore. The study sample consisted of patients suffering from schizophrenia and other psychotic disorders according to ICD 10 criteria (F20- F29) and who were maintaining remission  on any one of the second generation antipsychotics viz risperidone, olanzapine or quetiapine.

Results: Out of 154 subjects, 68 were on risperidone, 74 were on olanzapine, and 12 were on quetiapine. Most common ADRs reported were increased appetite (26%), weight gain (15%), tremors (14%), fatigue (14%), constipation (14%), dyspepsia (10%), somnolence (12%), decreased appetite (10%). Among these ADRs none of them were preventable and belonged to mild to moderate severity. Causality of adverse events was assessed by Naranjo algorithm; a probability scale for ADR. Severity was assessed by modified Hartwig and Seigel scale. Preventability was assessed using Schumock and Thronton criteria.

Conclusions: The most common ADRSs reported with SGAs were increased appetite and weight gain and the frequency of ADRs were higher with subjects receiving risperidone.


Keywords


Second generation antipsychotics, Adverse drug reactions, Pharmacovigilance

Full Text:

PDF

References


Dhikav V, Singh S, Anand KS. Adverse drug reaction monitoring in India. JIACM. 2004;5(1):27-33.

Chatterjee A, Sharma M, Gupta SK. Current Methods of Pharmcovigilance. In: Gupta SK, editor. Textbook of Pharmacovigilance. New Dehli. Jaypee Brothers Medical Publishers; 2011.

Fung M, Thornton A, Mybeck K, Hsiao-Hui J, Hornbuckle K, Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets- 1960 to 1999. Drug Inf J. 2001;35:293-317.

U.S. Department of Health and Human Services. U.S. Food and Drug Administration. (2011, September 1). FDA Drug Safety Communication: Serious Allergic Reactions Reported with the Use of Saphris (asenapine maleate)., at: http://www.fda.gov/Drugs/DrugSafety/ucm270243.htm. Accessed on 18 July, 2014.

U.S. Department of Health and Human Services. U.S. Food and Drug Administration, 2009. Labeling Change Request Letter for Antidepressant Medications. Available at http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096352.htm. Accessed on 18 July, 2014.

Abilify® (aripiprazole) prescribing information. (2011, February). From http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021436s032,021866s019,021713s024,021729s017lbl.pdf . Retrieved July 18, 2014

U.S. Department of Health and Human Services. U.S. Food and Drug Administration, 2005. Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Available at, http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm. Accessed on 18 July, 2014.

Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775-86.

Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627-32. Erratum in: CMAJ. 2007;176(11):1613.

Relprevv Z. (olanzapine pamoate) prescribing information. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022173lbl.pdf. Accessed on 18 July, 2014.

Clozaril (clozapine) prescribing information. (2013, March), Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019758s069s071lbl.pdf. Accessed on 18 July, 2014

Meltzer H. Antipsychotic agents & Lithium. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic & Clinical Pharmacology. 12th edition. New Dehli: Tata McGraw-Hill;2012:502-3.

Risperidone. Sweetman SC. editor. Martindale The Complete Drug Regference. 37th edition. London: Pharceutical Press;2011:1130-1133.

Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370.

Mathews M, Muzina DJ. Atypical antipsychotics: new drugs, new challenges. Cleve Clin J Med. 2007;74(8):597-606.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.

Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27:538.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229-32.

Mrugank BP and Hareesha RP. Prospective observational, non-randomized, parallel sequence study for assessment of adverse drug reactions due to chemotherapeutic treatment in different types of cancer patients. Int J Pharm Sci Res. 2013:4(1);386-91.

Meyer JM. Pharmacotherapy of Psychosis and Mania. In: Bruton LL. editor. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 12th edition. New York: Mc Graw Hill;2011:427.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23.

Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-43.

Olanzapine. Sweetman SC. editor. Martindale The Complete Drug Reference. 37th edition. London:Pharceutical Press; 2011:1117-1120

Quetiapine. Sweetman SC. editor. Martindale: The Complete Drug Reference. 37th edition. London: Pharceutical Press; 2011:1128-1130.

Shankar BR. Quetiapine-induced leucopenia and thrombocytopenia. Psychosomatics. 2007;48(6):530-1.

Carlini EL, Nappo SA. The pharmacovigilance of psychoactive medications in Brazil. Rev Bras Psiquiatr. 2003;25(4):200-5.

Dimitrova Z, Doma A, Petkova V, Getov I, Verkkunen E. Psychotropic drugs in Bulgaria-frequency and risk of adverse drug reactions. Boll Chim Farm. 2002;141(1):75-9.

Castberg I, Reimers A, Sandvik P, Aamo TO, Spigset O. Adverse drug reactions of antidepressants and antipsychotics: experience, knowledge and attitudes among Norwegian psychiatrists. Nord J Psychiatry. 2006;60(3):227-33.